bioRxiv Science⌕ Search

bioRxiv · 10.1101/2022.03.25.485740

Genetic mechanisms and biological processes underlying host response to ophidiomycosis (Snake Fungal Disease) inferred from tissue-specific transcriptome analyses.

Abstract

There is growing concern about infectious diseases in wildlife species caused by pathogenic fungi. Detailed knowledge exists about host pathology and the molecular mechanisms underlying host physiological response to some fungal diseases affecting amphibians and bats but is lacking for others with potentially significant impacts on large groups of animals. One such disease is ophidiomycosis (Snake Fungal Disease; SFD) which is caused by the fungus Ophidiomyces ophidiicola and impacts diverse species of snakes. Despite this potential, the biological mechanisms and molecular changes occurring during infection are unknown for any snake species. To gain this information, we performed a controlled experimental infection of captive Prairie rattlesnakes (Crotalus viridis) with O. ophidiicola at different temperatures. We then generated liver, kidney, and skin transcriptomes from control and infected snakes to assess tissue specific genetic responses to infection. Given previous SFD histopathological studies and the fact that snakes are ectotherms, we expected highest fungal activity on skin and a significant impact of temperature on host response. In contrast, we found that most of the differential gene expression was restricted to internal tissues and fungal-infected snakes showed transcriptome profiles indicative of long-term inflammation of specific tissues. Infected snakes at the lower temperature had the most pronounced overall host functional response whereas, infected snakes at the higher temperature had overall expression profiles similar to control snakes possibly indicating recovery from the disease. Overall, our results suggest SFD is a systemic disease with a chronic host response, unlike acute response shown by amphibians to Batrachochytrium dendrobatidis infections. Our analysis also generated a list of candidate protein coding genes that potentially mediate SFD response in snakes, providing tools for future comparative and evolutionary studies into variable species susceptibility to ophidiomycosis. Author summaryOphidiomycosis (Snake Fungal Disease; SFD) is an infectious fungal disease in snakes that has been documented in more than 40 species over the past 20 years. Though many snake species seem vulnerable to SFD, little is known about how snake physiology changes in response to infection with the causative fungus, Ophidiomyces ophidiicola. Here we report results from the first experimental transcriptomic study of SFD in a snake host. Our goals were to identify genes with a putative role in host response, use this information to understand what biological changes occur in different tissues in snakes when infected with O. ophidiicola, and determine if temperature has an impact in these ectothermic animals. We conclude that SFD is a systemic disease with a chronic inflammation leading to deterioration of internal organs and that these physiological impacts are more pronounced at low rather than high temperatures. These results contrast with fungal infections in amphibians where hosts show an acute response mostly restricted to skin. Our list of candidate genes carry utility in potentially diagnosing genetic susceptibility to SFD in snake species of conservation concern.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Mathur, S., Haynes, E., Allender, M. C., Gibbs, H. L.. 2022-03-27. Genetic mechanisms and biological processes underlying host response to ophidiomycosis (Snake Fungal Disease) inferred from tissue-specific transcriptome analyses.. https://doi.org/10.1101/2022.03.25.485740

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Midlife nonlinearities across scale in Biondi body amyloid formation in the human choroid plexus

Human choroid plexus epithelial cells (CPECs), which produce cerebrospinal fluid and form the blood-cerebrospinal fluid barrier, accumulate discrete intracellular amyloid inclusions called Biondi bodies (BBs). Using systematic manual and machine learning approaches on the choroid plexus glomus, we determined the percentages of CPECs containing thioflavin S-stained BBs as well as BB load and spatial distributions in whole slide images from 77 cases across the human lifespan. On average, BB prevalence was near zero until age 40, rose steeply in the 5th and 6th decades, and exceeded 50% after age 70. As prevalence plateaued, BB load continued to rise with age. Accelerated BB accumulation was seen in two cases of diabetic ketoacidosis, including a 16-year-old, while an 85-year-old with the relatively rare APOE2/E2 genotype had fewer BBs than expected. BB prevalence in the choroid plexus glomus was not associated with Alzheimer's disease, but was lower in females than males. Notably, spatial clustering of BBs was universal across cases while nearest-neighbor analyses suggested cell-to-cell, prion-like BB spread that can account for the nonlinearities seen at tissue and population scales. The abrupt, nonlinear BB accumulation during midlife coincides with or precedes other common aging-associated neuropathologies of the human brain, consistent with broad BB and choroid plexus contributions to brain aging and disease.

pathology↗

Elevated precontractile calcium set point is sustained by limited PMCA1 export in dystrophic muscle

Duchenne muscular dystrophy is caused by loss of dystrophin and marked by elevated muscle calcium, usually attributed to contraction-induced membrane damage. Whether calcium rises before muscle can contract, and what sustains it, is unresolved. In Caenorhabditis elegans embryos and patient-derived human myoblasts, dystrophic muscle carries an elevated resting calcium set point before contraction is possible. Embryonic calcium is elevated 400 minutes after fertilization, before movement is detectable or the neuromuscular junction forms. Silencing the plasma membrane calcium pump gene mca-1 raises calcium in wild-type but not dystrophic animals, whereas silencing its paralogue raises it in both: the limitation is specific to that export route. Dystrophic human myoblasts have less pump; pump inhibition or silencing increases calcium preferentially in healthy cells, and raising pump expression lowers calcium most in dystrophic cells. Constrained calcium export is an early, continuing determinant of the dystrophic set point.

pathology↗

Systematic comparison of gliflozins identifies a selective anti-calcifying effect of canagliflozin beyond canonical SGLT2 inhibition

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) provide important cardiorenal benefits in chronic kidney disease (CKD), but their effects on vascular calcification remain conflicting. Whether potential anti-calcifying effects are shared across gliflozins or involve mechanisms beyond canonical SGLT2 inhibition is unknown. Methods: We systematically compared canagliflozin, dapagliflozin and empagliflozin in a high-phosphate diet-induced mouse model of vascular calcification and complementary ex vivo and in vitro models, including rodent and human vascular tissues and vascular smooth muscle cells (VSMCs). Aortic transcriptional response was investigated by RNA sequencing. VSMC calcification, proliferation, migration, viability, glucose uptake and bioenergetics were investigated using complementary cellular assays, including OsteoSense staining, Annexin V/propidium iodide staining, radiolabeled 2-deoxyglucose uptake and Seahorse ATP rate analysis. SGLT2/1 expression was examined by RT-qPCR, Western blotting and immunofluorescence. We also evaluated sotagliflozin, a dual SGLT1/2 inhibitor, and mizagliflozin, a selective SGLT1 inhibitor. Results: Among the three gliflozins, only canagliflozin significantly reduced aortic calcification in vivo. Its anti-calcifying effect was also observed in rodent aortic rings, human vascular explants, cultured VSMCs and aortic rings from diabetic db/db mice. Aortic RNA-seq revealed that canagliflozin partially reversed HPD-induced transcriptional alterations, including changes in pro-calcific signaling and cellular metabolism, while some endothelial and inflammatory responses were shared among gliflozins. In mouse VSMCs, canagliflozin reduced calcification across all tested concentrations, dose-dependently decreased osteogenic marker expression, and reduced proliferation and migration. Increased apoptotic and damaged cell fractions were observed at higher concentrations, but not at lower concentrations. Canagliflozin also reduced glucose uptake and mitochondrial ATP production, without significantly affecting glycolytic ATP production. Neither dapagliflozin nor empagliflozin reproduced these cellular and metabolic effects at any of the concentrations tested. SGLT2 and SGLT1 expression was low or undetectable in vascular tissues and cells, and neither sotagliflozin nor mizagliflozin reproduced the anti-calcifying effect of canagliflozin in vivo or in vitro. Conclusions: Canagliflozin exhibits a selective anti-calcifying profile among the gliflozins tested, associated with changes in VSMC responses and cellular metabolism. These findings suggest that its vascular protective effects may involve mechanisms beyond canonical SGLT2 inhibition.

pathology↗